|
| 34910136 | Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. | Eur Heart J | 2022 |
| 34548531 | Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. | Scientific Reports | 2021 |
| 33858442 | Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region. | Lipids in Health and Disease | 2021 |
| 32522192 | Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey. | Lipids in Health and Disease | 2020 |
| 32144166 | Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. | Diabetes Care | 2020 |
| 32020062 | Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. | Nature Reviews Endocrinology | 2020 |
| 32220662 | Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease. | Atherosclerosis | 2020 |
| 31927126 | Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. | Am Heart J | 2020 |
| 31870497 | Corrigendum to "Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis" [Clin. Biochem. 64 (2019) 24-29]. | Clinical Biochemistry | 2020 |
| 33190147 | Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. | JAMA | 2020 |
| 31095332 | HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good? | Journal of Clinical Endocrinology and Metabolism | 2019 |
| 31700015 | The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits. | Scientific Reports | 2019 |
| 31722013 | Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL. | Clinical Science | 2019 |
| 31712677 | The relationship of circulating fibroblast growth factor 21 levels with pericardial fat: The Multi-Ethnic Study of Atherosclerosis. | Sci Rep | 2019 |
| 30452928 | High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). | Metabolism: Clinical and Experimental | 2019 |
| 30446181 | Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis. | Atherosclerosis | 2019 |
| 30365923 | Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. | Clinical Biochemistry | 2019 |
| 31301983 | Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. | Lancet Diabetes and Endocrinology,The | 2019 |
| 31018664 | Apolipoprotein A-I Protects Against Pregnancy-Induced Insulin Resistance in Rats. | Arteriosclerosis, Thrombosis, and Vascular Biology | 2019 |
| 31164165 | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initia | Cardiovascular Diabetology | 2019 |
| 30718702 | Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle. | Scientific Reports | 2019 |
| 31104887 | Status of PCSK9 Monoclonal Antibodies in Australia. | Heart Lung and Circulation | 2019 |
| 30771558 | HDL cholesterol and ASCVD risk stratification: A debate. | Atherosclerosis | 2019 |
| 29103916 | Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. | Journal of Clinical Lipidology | 2018 |
| 28795686 | HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. | Nat Rev Cardiol | 2018 |
| 30050317 | Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. | International Journal of General Medicine | 2018 |
| 30278356 | CETP inhibition, statins and diabetes. | Atherosclerosis | 2018 |
| 30125052 | Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. | Clin Cardiol | 2018 |
| 29358194 | Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. | Journal of the American Heart Association | 2018 |
| 29310989 | Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. | J Clin Lipidol | 2018 |
| 29351855 | The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. | Atherosclerosis | 2018 |
| 29487091 | Cholesteryl ester transfer protein and its inhibitors. | Journal of Lipid Research | 2018 |
| 29306454 | Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease. | International Journal of Cardiology | 2018 |
| 29618599 | Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. | Circulation | 2018 |
| 29705799 | Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. | Cardiology | 2018 |
| 29609759 | Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk. | Cardiology Clinics | 2018 |
| 29071331 | Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. | JAMA Cardiol | 2018 |
| 29735589 | High- Versus Low-Dose Statin: Effects on Cardiovascular Events and All-Cause Death. | Circulation | 2018 |
| 29779997 | Variations in time to benefit among clinical trials of cholesterol-lowering drugs. | Journal of Clinical Lipidology | 2018 |
| 27908917 | Erratum. Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism. Diabetes 2016;65:3610-3620. | | 2017 |
| 28775061 | Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. | J Am Heart Assoc | 2017 |
| 28863328 | Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. | Atherosclerosis | 2017 |
| 28431663 | Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial). | American Journal of Cardiology | 2017 |
| 28641153 | Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. | Atherosclerosis | 2017 |
| 28858077 | Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction: A propensity score matching analysis from the Korea Acute Myocardial Infarction Registry. | Medicine (United States) | 2017 |
| 28525554 | HDL cholesterol concentration or HDL function: which matters? | European Heart Journal | 2017 |
| 28518081 | Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT. | Journal of Visualized Experiments | 2017 |
| 29025709 | Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition. | Arteriosclerosis, Thrombosis, and Vascular Biology | 2017 |
| 28606915 | Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. | Clinical Chemistry | 2017 |
| 28514624 | Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. | New England Journal of Medicine | 2017 |